By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK Read about our COVID-19 Response. Site Search Corporate Governance Corporate Governance Documents Code of Business Conduct & Ethics Cerus is committed to maintaining the highest standards of business conduct and ethics. Our Code reflects the business practices and principles of behavior that support this commitment. Every employee, officer and director is expected to read and understand the Code and its application to the performance of his or her business responsibilities. Code of Business Conduct & Ethics (Revised July 2015) (opens in new window) Charter of the Nominating Corporate Governance Committee of the Board of Directors This charter describes the operating principles, processes, and responsibilities of the nominating and corporate governance committee of Cerus' board of directors. This committee oversees all aspects of the company's corporate governance functions, including identification, review, and recommendation of candidates to serve as directors. Nominating & Corporate Governance Committee Charter (Revised December 2017) (opens in new window) Compensation Committee Charter This charter describes the composition, authority, and responsibilities of the compensation committee of Cerus' board of directors. This committee develops and approves compensation policies, including executive compensation, stock option plans, bonus plans, and other similar programs. Cerus Compensation Committee Charter(Revised December 2017) (opens in new window) Audit Committee Charter This charter describes the purpose, composition, authority, and responsibilities of the audit committee of Cerus' board of directors. This committee guides the board of directors in fulfilling its oversight responsibilities with respect to corporate accounting and reporting practices. Cerus Audit Committee Charter(Revised October 2021) (opens in new window) Contacting the Audit Committee Employees, shareholders or third parties may communicate directly with the Cerus Audit Committee using the following address: Audit Committee Chairman c/o Cerus Corporation 1220 Concord Avenue, Suite 600 Concord, CA 94520 Corporate Governance Guidelines Cerus is committed to provide a structure within which our directors and management can pursue our objectives for the benefit of our stockholders. The Cerus Board of Directors has adopted these guidelines to promote the effective governance of Cerus. Cerus Corporate Governance Guidelines(December 14, 2017) (opens in new window) Conflict Minerals Cerus is committed to improving its diligence efforts and increasing transparency in our supply chain in order to work toward a conflict free supply chain. This Conflict Minerals Report is for the reporting period January 1 to December 31, 2020. Conflict-Minerals-Report (opens in new window) Comprehensive Compliance Program As part of Cerus Corporation’s continuing commitment to promote a culture of good corporate citizenship and responsibility, Cerus Corporation declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Program as mandated by this California law. To the best of our knowledge, as of July 1, 2017, Cerus Corporation believes that it is in compliance with its Comprehensive Compliance Program and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402. For questions about our Comprehensive Compliance Program, please contact us at legaldepartment@cerus.com. Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2021 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc. Back to top About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Powered By Q4 Inc. 5.56.0.1 (opens in new window) About Cerus